Fundraising FoxPolyplus
2 known investors
Find your way into Polyplus
Sign up to see every warm intro you have to Polyplus
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Polyplus team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Polyplus (a Sartorius company) develops FectoVIR-LV, an animal-component-free transfection reagent for producing lentiviral vectors in suspension HEK-293 cells at large manufacturing scale. It targets cell therapy producers, including those making CAR-T and other allogenic or autologous therapies, in the biomanufacturing sector.
Investors · 2
ARCHIMED Japanlisted by ARCHIMED JapanLyon · $10.8M – $1.1B
How we know: ARCHIMED Japan's portfolio page · Not right? Tell us
Warburg PincusreportedNew York
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Polyplus do?
- Polyplus (a Sartorius company) develops FectoVIR-LV, an animal-component-free transfection reagent for producing lentiviral vectors in suspension HEK-293 cells at large manufacturing scale. It targets cell therapy producers, including those making CAR-T and other allogenic or autologous therapies, in the biomanufacturing sector.
- Who are Polyplus's investors?
- Polyplus's investors include ARCHIMED Japan, Warburg Pincus.